In person ZoBio is pleased to attend the RSC-BMCS Fragment-Based Drug Discovery meeting in Cambridge this September. ZoBio will be represented by Johan Veerman | LinkedIn, Head of Chemistry, who will also present a poster entitled: Site-selective screening: Design, synthesis and application of stable S-adenosylmethionine-based probes for fragment screening against METTL3/14 We look forward to…

Molecular glues are rapidly emerging as a transformative modality in drug discovery, enabling novel mechanisms to modulate protein function through stabilization of protein–protein interactions. Yet discovering synthetic molecular glues de novo remains a major challenge, particularly due to the need to identify compounds that both engage a target and promote cooperative ternary complex formation.

Molecular glues are rapidly emerging as a transformative modality in drug discovery, enabling novel mechanisms to modulate protein function through stabilization of protein–protein interactions. Yet discovering synthetic molecular glues de novo remains a major challenge, particularly due to the need to identify compounds that both engage a target and promote cooperative ternary complex formation.

ZoBio is excited to attend TFMED 2026, a four-day transdisciplinary conference dedicated to next-generation therapeutic modalities, including molecular glues, PROTACs, nucleic acid-based therapies, and cell-based approaches.

The meeting brings together researchers, clinicians, and industry experts, offering in-depth scientific sessions, direct interaction with leading specialists, and valuable opportunities for networking and collaboration, with a strong focus on early-career scientists.